Targeting claudin 18.2 in gastric cancer: a review of emerging biologic agents
{{output}}
Introduction: Zolbetuximab, the first monoclonal antibody targeting claudin 18.2 (CLDN18.2), is approved as first-line treatment for patients with HER2-negative and CLDN18.2-positive gastric or gastroesophageal junction cancers, ... ...
